Clinical Trial Detail

NCT ID NCT03125928
Title Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Fox Chase Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST